Reflections on 40 Years of AIDS

Kevin M De Cock, Harold W Jaffe, James W Curran, Kevin M De Cock, Harold W Jaffe, James W Curran

Abstract

June 2021 marks the 40th anniversary of the first description of AIDS. On the 30th anniversary, we defined priorities as improving use of existing interventions, clarifying optimal use of HIV testing and antiretroviral therapy for prevention and treatment, continuing research, and ensuring sustainability of the response. Despite scientific and programmatic progress, the end of AIDS is not in sight. Other major epidemics over the past decade have included Ebola, arbovirus infections, and coronavirus disease (COVID-19). A benchmark against which to compare other global interventions is the HIV/AIDS response in terms of funding, coordination, and solidarity. Lessons from Ebola and HIV/AIDS are pertinent to the COVID-19 response. The fifth decade of AIDS will have to position HIV/AIDS in the context of enhanced preparedness and capacity to respond to other potential pandemics and transnational health threats.

Keywords: AIDS; COVID-19; Ebola; HIV; HIV/AIDS; SDGs; acquired immune deficiency syndrome; coronavirus disease; forty years; health security; history; human immunodeficiency virus.

References

    1. Centers for Disease Control (CDC). Pneumocystis pneumonia—Los Angeles. MMWR Morb Mortal Wkly Rep. 1981;30:250–2.
    1. De Cock KM, Jaffe HW, Curran JW. Reflections on 30 years of AIDS. Emerg Infect Dis. 2011;17:1044–8. 10.3201/eid/1706.100184
    1. Centers for Disease Control and Prevention. Compendium of evidence-based interventions and best practices for HIV prevention [cited 2021 Apr 18].
    1. Barré-Sinoussi F, Chermann J-C, Rey F, Nugeyre MT, Chamaret S, Gruest J, et al. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science. 1983;220:868–71. 10.1126/science.6189183
    1. Popovic M, Sarngadharan MG, Read E, Gallo RC. Detection, isolation, and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS. Science. 1984;224:497–500. 10.1126/science.6200935
    1. Hahn BH, Shaw GM, De Cock KM, Sharp PM. AIDS as a zoonosis: scientific and public health implications. Science. 2000;287:607–14. 10.1126/science.287.5453.607
    1. France D. How to survive a plague: the inside story of how citizens and science tamed AIDS. New York: Alfred Knopf; 2016.
    1. Merson M, Inrig S. The AIDS pandemic. Searching for a global response. 2018. Cham (Switzerland); Springer International Publishing; 2018. p. 25–113.
    1. Piot P. No time to lose. A life in pursuit of deadly viruses. New York: W.W. Norton & Co.; 2012. p. 316–34.
    1. Fauci AS, Eisinger RW. PEPFAR—15 years and counting the lives saved. N Engl J Med. 2018;378:314–6. 10.1056/NEJMp1714773
    1. Joint United Nations Programme on HIV/AIDS. UNAIDS data 2020. [cited 2021 Apr 18].
    1. Centers for Disease Control and Prevention. HIV surveillance report, 2018. (Preliminary); vol. 30 [cited 2021 Mar 14].
    1. Peters PJ, Pontones P, Hoover KW, Patel MR, Galang RR, Shields J, et al.; Indiana HIV Outbreak Investigation Team. HIV infection linked to injection use of oxymorphone in Indiana, 2014–2015. N Engl J Med. 2016;375:229–39. 10.1056/NEJMoa1515195
    1. Abdool Karim Q, Abdool Karim SS, Frohlich JA, Grobler AC, Baxter C, Mansoor LE, et al.; CAPRISA 004 Trial Group. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science. 2010;329:1168–74. 10.1126/science.1193748
    1. Nel A, van Niekerk N, Kapiga S, Bekker L-G, Gama C, Gill K, et al.; Ring Study Team. Safety and efficacy of a dapivirine vaginal ring for HIV prevention in women. N Engl J Med. 2016;375:2133–43. 10.1056/NEJMoa1602046
    1. Baeten JM, Palanee-Phillips T, Brown ER, Schwartz K, Soto-Torres LE, Govender V, et al.; MTN-020–ASPIRE Study Team. Use of a vaginal ring containing dapivirine for HIV-1 prevention in women. N Engl J Med. 2016;375:2121–32. 10.1056/NEJMoa1506110
    1. Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, et al.; iPrEx Study Team. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363:2587–99. 10.1056/NEJMoa1011205
    1. Baeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, Wangisi J, et al.; Partners PrEP Study Team. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012;367:399–410. 10.1056/NEJMoa1108524
    1. McCormack S, Dunn DT, Desai M, Dolling DI, Gafos M, Gilson R, et al. Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial. Lancet. 2016;387:53–60. 10.1016/S0140-6736(15)00056-2
    1. Molina J-M, Capitant C, Spire B, Pialoux G, Cotte L, Charreau I, et al.; ANRS IPERGAY Study Group. On-demand preexposure prophylaxis in men at high risk for HIV-1 infection. N Engl J Med. 2015;373:2237–46. 10.1056/NEJMoa1506273
    1. National Institute for Health and Care Excellence. Pre-exposure prophylaxis of HIV in adults at high risk: Truvada (emtricitabine/tenofovir disoproxil). Evidence summary. [ESNM78] [cited 2021 Mar 14].
    1. National Institutes of Health. Long-acting injectable form of HIV prevention outperforms daily pill in NIH study [cited 2021 Apr 18].
    1. National Institutes of Health. NIH study finds long-acting injectable drug prevents HIV acquisition in cisgender women [cited 2021 Apr 18].
    1. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al.; HPTN 052 Study Team. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365:493–505. 10.1056/NEJMoa1105243
    1. Granich RM, Gilks CF, Dye C, De Cock KM, Williams BG. Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet. 2009;373:48–57. 10.1016/S0140-6736(08)61697-9
    1. Iwuji CC, Orne-Gliemann J, Larmarange J, Balestre E, Thiebaut R, Tanser F, et al.; ANRS 12249 TasP Study Group. Universal test and treat and the HIV epidemic in rural South Africa: a phase 4, open-label, community cluster randomised trial. Lancet HIV. 2018;5:e116–25. 10.1016/S2352-3018(17)30205-9
    1. Havlir DV, Balzer LB, Charlebois ED, Clark TD, Kwarisiima D, Ayieko J, et al. HIV testing and treatment with the use of a community health approach in rural Africa. N Engl J Med. 2019;381:219–29. 10.1056/NEJMoa1809866
    1. Makhema J, Wirth KE, Pretorius Holme M, Gaolathe T, Mmalane M, Kadima E, et al. Universal testing, expanded treatment, and incidence of HIV infection in Botswana. N Engl J Med. 2019;381:230–42. 10.1056/NEJMoa1812281
    1. Hayes RJ, Donnell D, Floyd S, Mandla N, Bwalya J, Sabapathy K, et al.; HPTN 071 (PopART) Study Team. HPTN 071 (PopART) Study Team. Effect of universal testing and treatment on HIV incidence—HPTN 071 (PopART). N Engl J Med. 2019;381:207–18. 10.1056/NEJMoa1814556
    1. Lundgren JD, Babiker AG, Gordin F, Emery S, Grund B, Sharma S, et al.; INSIGHT START Study Group. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med. 2015;373:795–807. 10.1056/NEJMoa1506816
    1. Danel C, Moh R, Gabillard D, Badje A, Le Carrou J, Ouassa T, et al.; TEMPRANO ANRS 12136 Study Group. TEMPRANO ANRS 12136 Study Group. A trial of early antiretrovirals and isoniazid preventive therapy in Africa. N Engl J Med. 2015;373:808–22. 10.1056/NEJMoa1507198
    1. Rodger AJ, Cambiano V, Bruun T, Vernazza P, Collins S, van Lunzen J, et al.; PARTNER Study Group. Sexual activity without condoms and risk of HIV transmission in serodifferent couples when the HIV-positive partner is using suppressive antiretroviral therapy. JAMA. 2016;316:171–81. 10.1001/jama.2016.5148
    1. Nwokolo N, Hill A, McOwan A, Pozniak A. Rapidly declining HIV infection in MSM in central London. Lancet HIV. 2017;4:e482–3. 10.1016/S2352-3018(17)30181-9
    1. Grulich AE, Guy R, Amin J, Jin F, Selvey C, Holden J, et al.; Expanded PrEP Implementation in Communities New South Wales (EPIC-NSW) research group. Population-level effectiveness of rapid, targeted, high-coverage roll-out of HIV pre-exposure prophylaxis in men who have sex with men: the EPIC-NSW prospective cohort study. Lancet HIV. 2018;5:e629–37. 10.1016/S2352-3018(18)30215-7
    1. Fauci AS, Redfield RR, Sigounas G, Weahkee MD, Giroir BP. Ending the HIV epidemic: a plan for the United States. JAMA. 2019;321:844–5. 10.1001/jama.2019.1343
    1. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R, et al.; MOPH-TAVEG Investigators. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med. 2009;361:2209–20. 10.1056/NEJMoa0908492
    1. Desrosiers RC. Protection against HIV acquisition in the RV144 trial. J Virol. 2017;91:e00905–17. 10.1128/JVI.00905-17
    1. National Institutes of Health. Experimental HIV vaccine regimen ineffective in preventing HIV [cited 2021 Apr 18].
    1. National Institutes of Health. Antibody infusions prevent acquisition of some HIV strains, NIH studies find [cited 2021 Apr 18].
    1. Ghys PD, Williams BG, Over M, Hallett TB, Godfrey-Faussett P. Epidemiological metrics and benchmarks for a transition in the HIV epidemic. PLoS Med. 2018;15:e1002678. 10.1371/journal.pmed.1002678
    1. Grabowski MK, Serwadda DM, Gray RH, Nakigozi G, Kigozi G, Kagaayi J, et al.; Rakai Health Sciences Program. HIV prevention efforts and incidence of HIV in Uganda. N Engl J Med. 2017;377:2154–66. 10.1056/NEJMoa1702150
    1. Borgdorff MW, Kwaro D, Obor D, Otieno G, Kamire V, Odongo F, et al. HIV incidence in western Kenya during scale-up of antiretroviral therapy and voluntary medical male circumcision: a population-based cohort analysis. Lancet HIV. 2018;5:e241–9. 10.1016/S2352-3018(18)30025-0
    1. Das P, Horton R. Beyond the silos: integrating HIV and global health. Lancet. 2018;392:260–1. 10.1016/S0140-6736(18)31466-1
    1. Eisinger RW, Fauci AS. Ending the HIV/AIDS Pandemic. Emerg Infect Dis. 2018;24:413–6. 10.3201/eid2403.171797
    1. De Cock KM, Simone PM, Davison V, Slutsker L. The new global health. Emerg Infect Dis. 2013;19:1192–7. 10.3201/eid1908.130121
    1. Lo TQ, Marston BJ, Dahl BA, De Cock KM. Ebola: Anatomy of an Epidemic. Annu Rev Med. 2017;68:359–70. 10.1146/annurev-med-052915-015604
    1. World Health Organization. Ending an Ebola outbreak in a conflict zone [cited 2021 Apr 18].
    1. Arwady MA, Bawo L, Hunter JC, Massaquoi M, Matanock A, Dahn B, et al. Evolution of ebola virus disease from exotic infection to global health priority, Liberia, mid-2014. Emerg Infect Dis. 2015;21:578–84. 10.3201/eid2104.141940
    1. Mulangu S, Dodd LE, Davey RT Jr, Tshiani Mbaya O, Proschan M, Mukadi D, et al.; PALM Writing Group; PALM Consortium Study Team. PALM Consortium Study Team. A randomized, controlled trial of Ebola virus disease therapeutics. N Engl J Med. 2019;381:2293–303. 10.1056/NEJMoa1910993
    1. Henao-Restrepo AM, Camacho A, Longini IM, Watson CH, Edmunds WJ, Egger M, et al. Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ça Suffit!). Lancet. 2017;389:505–18. 10.1016/S0140-6736(16)32621-6
    1. World Health Organization. Yellow fever outbreak Angola, Democratic Republic of the Congo and Uganda 2016–2017 [cited 2021 Mar 14].
    1. Paixão ES, Teixeira MG, Rodrigues LC. Zika, chikungunya and dengue: the causes and threats of new and re-emerging arboviral diseases. BMJ Glob Health. 2018;3(Suppl 1):e000530. 10.1136/bmjgh-2017-000530
    1. Musso D, Ko AI, Baud D. Zika virus infection—after the pandemic. N Engl J Med. 2019;381:1444–57. 10.1056/NEJMra1808246
    1. World Health Organization. International Health Regulations (2005). 2nd ed. Geneva: The Organization; 2008.
    1. United Nations. The 17 goals [cited 2021 Apr 18].
    1. Institute for Health Metrics and Evaluation. Financing global health 2019. Tracking health spending in a time of crisis [cited 2021 Mar 14].
    1. World Health Organization. Weekly epidemiological update on COVID-19—13 April 2021. [cited 2021 Apr 27].

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe